Comparison
Creatine Monohydrate vs Noopept
Side-by-side of Creatine Monohydrate and Noopept. Every row below is pulled from the compound schema and will update as our data grows. For deeper reads, follow through to each compound page.
Creatine Monohydrate
Creatine monohydrate supplement guide: 3-5 g/day raises phosphocreatine stores, lifts anaerobic output 5-15%, supports lean mass and cognition under sleep loss.
Noopept
Noopept cognitive enhancer profile: 10 to 30 mg dosage, dipeptide nootropic mechanism, memory effects, and how it compares to piracetam.
Effects at a glance
Creatine Monohydrate
- •Increases anaerobic strength and power output by ~5 to 15% across multiple training studies
- •Adds ~1 to 2 kg of lean body mass over 4 to 12 weeks, partly intracellular water and partly true tissue gain
- •Improves 1-rep max on bench and squat by ~5 to 10% versus placebo in resistance-trained adults
- •Cognitive benefit appears mainly under sleep deprivation or high mental load, less so in well-rested individuals
- •Saturation reached in ~28 days at 3 to 5 g/day, or ~5 to 7 days with a 20 g/day loading phase
- •No evidence of renal harm in healthy adults across long-term studies; caution in pre-existing severe renal disease
Noopept
- •Russian dipeptide nootropic developed in the 1990s, registered in Russia 2002 for cognitive impairment
- •Roughly 1,000-fold higher per-mg potency than piracetam; therapeutic dose 10 to 30 mg/day
- •Active metabolite cycloprolylglycine modulates AMPA receptors and increases NGF and BDNF in rodent hippocampus
- •Russian RCTs in stroke recovery and vascular cognitive impairment show modest improvements over 4 to 8 weeks
- •Western evidence base is essentially absent; healthy-adult enhancement trials have not been published
- •Unscheduled in the US but not approved for human consumption; UK is prescription-only since 2014
Side-by-side
| Attribute | Creatine Monohydrate | Noopept |
|---|---|---|
| Category | supplement | nootropic |
| Also known as | creatine | GVS-111, N-phenylacetyl-L-prolylglycine ethyl ester, Omberacetam |
| Half-life (hr) ↗ | 3 | 0.7 |
| Typical dose (mg) ↗ | 5000 | 20 |
| Dosing frequency | daily | 2 to 3 times daily, last dose before mid-afternoon |
| Routes | oral | oral, sublingual |
| Onset (hr) | 168 | 0.5 |
| Peak (hr) | - | 1 |
| Molecular weight | 149.15 | 318.37 |
| Molecular formula | C4H9N3O2 | C17H22N2O4 |
| Mechanism | Donates a phosphate group to ADP via creatine kinase, regenerating ATP during high-intensity, short-duration efforts. | Hydrolyzed to active metabolite cycloprolylglycine; AMPA receptor modulation, BDNF and NGF upregulation, antioxidant and antiexcitotoxic effects. |
| Legal status | Dietary supplement (most jurisdictions) | Approved in Russia and CIS states; prescription-only in UK; unscheduled and unapproved in US, EU varies |
| WADA status | allowed | unknown |
| DEA / Rx | OTC supplement | Not scheduled in the US |
| Pregnancy | Insufficient data | Not recommended |
| CAS | 57-00-1 | 157115-85-0 |
| PubChem CID | 586 | 183503 |
| Wikidata | Q408389 | Q4321022 |
Safety profile
Creatine Monohydrate
Common side effects
- water retention
- mild GI upset at loading doses
- weight gain (2 to 4 lb from intracellular water)
Contraindications
- severe renal impairment
Interactions
- caffeine (high-dose acute): mixed data on ergogenic interference; chronic use appears compatible(minor)
- nephrotoxic drugs (NSAIDs, cyclosporine): theoretical additive renal strain in at-risk patients(moderate)
Noopept
Common side effects
- headache
- irritability
- sleep disturbance with late-day dosing
- occasional blood pressure elevation
Contraindications
- pregnancy
- lactation
- pediatric use
- severe hepatic impairment
- severe renal impairment
Interactions
- memantine and other glutamatergic agents: theoretical AMPA-pathway interaction(minor)
- antidepressants: theoretical effect via BDNF axis, undocumented(minor)
- antihypertensives: occasional blood pressure elevation may require monitoring(minor)
Which Should You Take?
Creatine Monohydrate comes out ahead for most readers on the criteria we weight: 3 catalogued goals, OTC dietary supplement, oral dosing, with a Tier-A outcome catalogued. Noopept is the right call when one of the conditionals below applies.
- → If your priority is strength or hypertrophy, pick Creatine Monohydrate.
- → If your priority is post-training recovery, pick Creatine Monohydrate.
- → If your priority is memory, pick Noopept.
- → If your priority is stress and HPA-axis regulation, pick Noopept.
Edge case: If you want to avoid controlled substance, Creatine Monohydrate is the more accessible choice.
Default choice: Creatine Monohydrate. Lower friction to source, a Tier-A evidence outcome catalogued, and broader goal coverage. Reach for Noopept only if your priority sits squarely in the goals it owns above.
This verdict is generated from each compound's schema (goals, legal status, evidence outcomes, dosing route). It updates automatically as our compound data evolves; the deeper read sits on each individual compound page.
Common questions
What is the difference between Creatine Monohydrate and Noopept?
Creatine Monohydrate and Noopept differ in category (supplement vs nootropic), mechanism, and typical dosing. See the side-by-side table for full details.
Which has a longer half-life, Creatine Monohydrate or Noopept?
Creatine Monohydrate half-life is 3 hours; Noopept half-life is 0.7 hours.
Can you stack Creatine Monohydrate with Noopept?
Stack compatibility depends on mechanism overlap, legal status, and individual response. Check each compound page for specific interactions and contraindications before combining.
Go deeper